KalVista Pharmaceuticals (KALV) Receivables (2017 - 2025)
KalVista Pharmaceuticals recorded quarterly Receivables of $1.9 million in Q3 2025, down 73.97% quarter-over-quarter from $7.3 million in Q4 2017.
KalVista Pharmaceuticals' Receivables history runs 2 years deep, the most recent figure standing at $1.9 million for Q3 2025.
- In Q3 2025, Receivables changed N/A year-over-year to $1.9 million; the TTM figure through Jul 2025 stood at $1.9 million (changed N/A YoY), while the FY2017 annual figure was $7.6 million, changed N/A from the prior year.
- Receivables came in at $1.9 million for Q3 2025 at KalVista Pharmaceuticals, down from $7.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.9 million in Q3 2025 to a low of $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 1.90 Mn |
| Oct 31, 2017 | 7.30 Mn |
| Jul 31, 2017 | 7.37 Mn |
| Apr 30, 2017 | 7.60 Mn |